Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers.
2019-nCoV Vaccine mRNA-1273
/ administration & dosage
Adult
BNT162 Vaccine
/ administration & dosage
COVID-19
/ epidemiology
COVID-19 Vaccines
/ administration & dosage
Cross-Sectional Studies
Female
Healthy Volunteers
Humans
Immunization Schedule
Immunoglobulin G
/ blood
Immunosuppressive Agents
Japan
/ epidemiology
Male
Middle Aged
Seroepidemiologic Studies
Vaccination
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 09 2022
29 09 2022
Historique:
received:
15
04
2022
accepted:
19
09
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Several factors related to anti-spike(S) IgG antibody titers after mRNA COVID-19 vaccination have been elucidated, but the magnitude of the effects of each factor has not been fully understood. This cross-sectional study assessed anti-S and anti-nucleocapsid (N) antibody titers on 3744 healthy volunteers (median age, 36 years; IQR, 24-49 years; females, 59.0%) who received two doses of mRNA-1273 or BNT162b2 vaccine and completed a survey questionnaire. Multiple regression was conducted to identify factors associated with antibody titers. All but one participant tested positive for anti-S antibodies (99.97%). The following factors were independently and significantly associated with high antibody titer: < 3 months from vaccination (ratio of means 4.41); mRNA-1273 vaccine (1.90, vs BNT162b2); anti-N antibody positivity (1.62); age (10's: 1.50, 20's: 1.37, 30's: 1.26, 40's: 1.16, 50's: 1.15, vs ≧60's); female (1.07); immunosuppressive therapy (0.54); current smoking (0.85); and current drinking (0.96). The largest impact on anti-S IgG antibody titers was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection (anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors.
Identifiants
pubmed: 36175506
doi: 10.1038/s41598-022-20747-x
pii: 10.1038/s41598-022-20747-x
pmc: PMC9520958
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin G
0
Immunosuppressive Agents
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16294Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
World Health Organization WHO. Available at: https://covid19.who.int /. Accessed 15 Feb 2022.
Ministry of Health, Labour and Welfare Japan. Available at: https://covid19.mhlw.go.jp/ . Accessed 15 Feb 2022.
Prime Minister’s Office Japan. Available at: https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html . Accessed 15 Feb 2022.
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Pfizer-BioNTech. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee Briefing Document. . Available at: https://www.fda.gov/media/144246/download .
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389
Favresse, J. et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg. Microbes Infect. 10, 1495–1498 (2021).
doi: 10.1080/22221751.2021.1953403
Tretyn, A. et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells 10, 1 (2021).
doi: 10.3390/cells10081952
Harris, R. J. et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J. Infect. 82, 162–169 (2021).
doi: 10.1016/j.jinf.2021.03.015
Wheeler, S. E. et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol. Spectr. 9, e0034121 (2021).
doi: 10.1128/Spectrum.00341-21
Wisnewski, A. V., Campillo Luna, J. & Redlich, C. A. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS ONE 16, e0249499 (2021).
doi: 10.1371/journal.pone.0249499
Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).
doi: 10.1016/j.lanepe.2021.100208
Danese, E. et al. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: A three-case series. Clin. Chem. Lab. Med. 59, 1585–1591 (2021).
doi: 10.1515/cclm-2021-0339
Coggins, S. A. A. et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. medRxiv 1, 1 (2021).
Walsh, E. E. et al. Safety and immunogenicity of Two RNA-based covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
doi: 10.1056/NEJMoa2027906
Müller, L. et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 Coronavirus disease 2019 vaccination. Clin. Infect. Dis. 73, 2065–2072 (2021).
doi: 10.1093/cid/ciab381
Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 9, 999–1009 (2021).
doi: 10.1016/S2213-2600(21)00220-4
Boyarsky, B. J. et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325, 2204–2206 (2021).
doi: 10.1001/jama.2021.7489
Grupper, A. et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant 21, 2719–2726 (2021).
doi: 10.1111/ajt.16615
Rabinowich, L. et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J. Hepatol. 75, 435–438 (2021).
doi: 10.1016/j.jhep.2021.04.020
Deepak, P. et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 1, 1 (2021).
Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 6, 1 (2021).
doi: 10.1126/sciimmunol.abj1031
Sattler, A. et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J. Clin. Invest. 131, 1 (2021).
doi: 10.1172/JCI150175
Tenforde, M. W. et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. Clin. Infect. Dis. 1, 1 (2021).
Kontopoulou, K. et al. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: Real-world evidence from Greek healthcare workers. J. Med. Microbiol. 70, 1 (2021).
doi: 10.1099/jmm.0.001387
Olariu, T. R., Ursoniu, S., Marincu, I. & Lupu, M. A. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine: A 7-month follow-up study. Medicina 1, 57 (2021).
Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981–984 (2021).
doi: 10.1038/s41591-021-01325-6
Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).
doi: 10.1056/NEJMc2101667
Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 397, 1178–1181 (2021).
doi: 10.1016/S0140-6736(21)00502-X
Blain, H. et al. Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA 1, 1 (2021).
Montoya, J. G. et al. Differences in IgG antibody responses following BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. Microbiol. Spectr. 9, e0116221 (2021).
doi: 10.1128/Spectrum.01162-21
Kitagawa, H. et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 1, 1 (2022).
Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).
doi: 10.1056/NEJMoa2022483
Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y. & Nakazono, A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS ONE 16, e0257668 (2021).
doi: 10.1371/journal.pone.0257668
Tani, N. et al. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. Vaccine 40, 2062–2067 (2022).
doi: 10.1016/j.vaccine.2022.02.025
Uwamino, Y. et al. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine 40, 1019–1025 (2022).
doi: 10.1016/j.vaccine.2022.01.002
Ortho Clinical Diagnostics. VITROS Anti–SARS-CoV-2 S1 Quant IgG reagent pack. 2021.
World Health Organization WHO. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. 2020, WHO Expert Committee on Biological Standardization. Available at: https://cdn.who.int/media/docs/default-source/biologicals/ecbs/bs-2020-2403-sars-cov-2-ab-ik-17-nov-2020_4ef4fdae-e1ce-4ba7-b21a-d725c68b152b.pdf?sfvrsn=662b46ae_8&download=true .
Roche Diagnostics. Available at: https://diagnostics.roche.com/jp/ja/products/params/elecsys-anti-sars-cov-2.html .
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
doi: 10.1038/s41586-021-03207-w
Keshavarz, B. et al. Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. Front. Immunol. 13, 850987 (2022).
doi: 10.3389/fimmu.2022.850987
Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 326, 1533–1535 (2021).
doi: 10.1001/jama.2021.15125
Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).
doi: 10.1016/S0140-6736(21)00432-3
Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–714.e11 (2021).
doi: 10.1016/j.cell.2021.10.011
Hall, V. G. et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 23, 380–385 (2022).
doi: 10.1038/s41590-021-01126-6
Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H. & Alter, G. Sex differences in vaccine-induced humoral immunity. Semin. Immunopathol. 41, 239–249 (2019).
doi: 10.1007/s00281-018-0726-5
Klein, S. L., Marriott, I. & Fish, E. N. Sex-based differences in immune function and responses to vaccination. Trans. R Soc. Trop. Med. Hyg. 109, 9–15 (2015).
doi: 10.1093/trstmh/tru167
Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 145, 1309–1321 (2020).
doi: 10.1016/j.jaci.2020.03.017
Collier, A. Y. et al. COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. J. Infect. Dis. 1, 1 (2021).
Watanabe, M. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab. Res. Rev. 38, e3465 (2022).
doi: 10.1002/dmrr.3465
Kageyama, T. et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin. Microbiol. Infect. 27, 1861 (2021).
doi: 10.1016/j.cmi.2021.07.042
L’Huillier, A. G. et al. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study. Clin. Microbiol. Infect 1, 1 (2021).
Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 1, 371 (2021).
Yamamoto, S. et al. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. Vaccine 40, 1924–1927 (2022).
doi: 10.1016/j.vaccine.2022.02.052
Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195–197 (2021).
doi: 10.1038/s41577-021-00526-x
Hiroshima Prefectural Government’s official site. Available at: https://www.pref.hiroshima.lg.jp/site/2019-ncov/ . Accessed 13 Sep 2021.
He, J., Guo, Y., Mao, R. & Zhang, J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J. Med. Virol. 93, 820–830 (2021).
doi: 10.1002/jmv.26326
National institution of infectious diseases Japan. National Institute of Infectious Diseases. Field Briefing: diamond Princess COVID-19 cases (2020).
Nishiura, H. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int. J. Infect. Dis. 94, 154–155 (2020).
doi: 10.1016/j.ijid.2020.03.020
Sugiyama, A. et al. A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020. Environ. Health Prev. Med. 27, 30 (2022).
doi: 10.1265/ehpm.22-00016
Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230 (2020).
doi: 10.1126/science.abd7728
Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598–1607 (2020).
doi: 10.1038/s41564-020-00813-8